NCT06203977CompletedPhase 2
Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
Phase 2 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 8 Dec 2023
- Start date
- 15 Nov 2024
- Primary completion date
- 4 Apr 2026
- Lead sponsor
- Hamilton Health Sciences Corporation
- Diseases
- Chronic kidney disease
- NCT number
- NCT06203977
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 96
- From 15 Nov 2024 to the primary completion date, 4 Apr 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently treated with and cannot withdraw colchicine due to medical necessity; or
- Prior self-reported intolerance to colchicine at a dose of 0.6 mg daily or lower; or
- Anticipated living donor renal transplant within the next 6 months; or
- Using a strong inhibitor of p-glycoprotein or strong inhibitor of CYP3A4 in the last 14 days; or
Other illness
- Known allergy/sensitivity to colchicine; or
- Cirrhosis, or chronic active hepatitis; or
Lab values
- Pre-existent neuromuscular disease or persistent serum CK level \> 3 times the upper limit of normal as measured within the past 60 days and determined to be non-transient through repeat testing; or
- Patient with any of the following within the past 60 days:
- white blood cell count \< 3.0 X 109/L; or
- platelet count \<110 X 109/L; or
- ALT or AST \> 3 times the upper limit of normal (ULN); or
- total bilirubin \> 2 times ULN and not due to Gilbert syndrome.
Other
- Currently pregnant or planning to become pregnant or breastfeed during the study; or
- Of childbearing potential AND do not have a negative pregnancy test OR do not agree to use two forms of contraception for the duration of the study; or
- B12 deficiency not managed with intramuscular supplementation; or
- Uncontrolled chronic diarrhea; or
- Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Who the study is looking for
- One of either:
- 1.2 Estimated GFR using CKD-EPI 2021 equation of ≤30 ml/min/1.73m2 on at least two occasions separated by at least 2 months and do not yet require dialysis and are not expected by their treating nephrologist to require dialysis in the next 6 months (REPAIR CKD cohort), or 1.3 receiving chronic maintenance dialysis 2 or more times per week for the previous 90 days (REPAIR Dialysis cohort);
- Age ≥18 years
- Provide informed consent to participate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Hospital Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| St. Joseph's Healthcare Hamilton Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
| London Health Sciences Centre Coordinator of this site? Confirm its status | London | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.